SANTA CRUZ BIOTECHNOLOGY, INC.

O-GlcNAc (RL2): sc-59624



BACKGROUND

O-GlcNAc (O-linked N-acetylglucosamine) is a form of protein glycosylation found exclusively in the nucleus and cytoplasm of eukaryotic cells. Many proteins are modified at their serine and threonine hydroxyl groups by the attachment of O-GlcNAc. Proteins that regulate trafficking into and out of the nuclear pore are extensively O-GlcNAcylated. Phosphorylated O-GlcNAc proteins form reversible multimeric complexes with other proteins and these associations are often regulated by phosphorylation. O-GlcNAc proteins may play a key role in pathogenesis of tumors and various cancer cells. O-GlcNAc residues regulate the assembly of the preinitiation complex and are therefore important in transcriptional initiation. Cytoskeletal and membrane O-GlcNAc proteins maintain erythrocyte cell shape and regulate the degradation of proteins responsible for lesions in Alzheimer's disease.

SOURCE

O-GIcNAc (RL2) is a mouse monoclonal antibody raised against pore complex-lamina fraction purified from liver nuclear envelopes of rat origin.

PRODUCT

Each vial contains 200 μg IgG_1 kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

O-GIcNAc (RL2) is available conjugated to agarose (sc-59624 AC), 500 μ g/ 0.25 ml agarose in 1 ml, for IP; to HRP (sc-59624 HRP), 200 μ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-59624 PE), fluorescein (sc-59624 AF1C), Alexa Fluor[®] 488 (sc-59624 AF488), Alexa Fluor[®] 546 (sc-59624 AF546), Alexa Fluor[®] 594 (sc-59624 AF594) or Alexa Fluor[®] 647 (sc-59624 AF647), 200 μ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor[®] 680 (sc-59624 AF680) or Alexa Fluor[®] 790 (sc-59624 AF790), 200 μ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

O-GlcNAc (RL2) is recommended for detection of O-GlcNAc in a broad range of species, including mammals, insects, worms, plants and filamentous fungi by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)] and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Positive Controls: HeLa nuclear extract: sc-2120, AT3B-1 whole cell lysate: sc-364372 or NIH/3T3 nuclear extract: sc-2138.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA





0-GlcNAc (RL2): sc-59624. Western blot analysis of 0-GlcNAc modified proteins expression in AT38-1 whole cell lysate (A) and NIH/3T3 nuclear extract (B).

O-GlcNAc (RL2): sc-59624. Immunofluorescence staining of formalin-fixed HeLa cells showing nuclear and cytoplasmic localization. Kindly provided by Yang Xiang, Ph. D., Division of Newborn Medicine, Boston Children's Hospital, Cell Biology Department, Harvard Medical School (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human gall bladder tissue showing nuclear staining of glandular cells (B).

SELECT PRODUCT CITATIONS

- Sohn, K.C., et al. 2004. OGT functions as a catalytic chaperone under heat stress response: a unique defense role of OGT in hyperthermia. Biochem. Biophys. Res. Commun. 322: 1045-1051.
- Kaushik, A.K., et al. 2016. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat. Commun. 7: 11612.
- Qiu, H., et al. 2017. Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma. Mol. Carcinog. 56: 258-271.
- 4. Hu, J., et al. 2017. Augmented O-GlcNAc signaling via glucosamine attenuates oxidative stress and apoptosis following contrast-induced acute kidney injury in rats. Free Radic. Biol. Med. 103: 121-132.
- Vasconcelos-Dos-Santos, A., et al. 2017. Hyperglycemia exacerbates colon cancer malignancy through hexosamine biosynthetic pathway. Oncogenesis 6: e306.
- Kubota, Y., et al. 2017. WGA-based lectin affinity gel electrophoresis: a novel method for the detection of O-GlcNAc-modified proteins. PLoS ONE 12: e0180714.
- 7. Cox, N.J., et al. 2018. Dynamic glycosylation governs the vertebrate COPII protein trafficking pathway. Biochemistry 57: 91-107.
- Kongkaew, T., et al. 2018. O-GlcNAcylation in oral squamous cell carcinoma. J. Oral Pathol. Med. 47: 260-267.
- Draime, A., et al. 2018. The O-GlcNAc transferase OGT interacts with and post-translationally modifies the transcription factor HOXA1. FEBS Lett. 592: 1185-1201.

RESEARCH USE

For research use only, not for use in diagnostic procedures.